| Title: | Adalimumab in Active and Inactive, Non-Infectious Uveitis : Global Results from the VISUAL I and VISUAL II Trials |
| Authors: | Goto, Hiroshi Browse this author →KAKEN DB |
| Zako, Masahiro Browse this author →KAKEN DB |
| Namba, Kenichi Browse this author →KAKEN DB |
| Hashida, Noriyasu Browse this author →KAKEN DB |
| Kaburaki, Toshikatsu Browse this author →KAKEN DB |
| Miyazaki, Masanori Browse this author →KAKEN DB |
| Sonoda, Koh-Hei Browse this author →KAKEN DB |
| Abe, Toshiaki Browse this author →KAKEN DB |
| Mizuki, Nobuhisa Browse this author →KAKEN DB |
| Kamoi, Koju Browse this author →KAKEN DB |
| Brezin, Antoine P. Browse this author |
| Dick, Andrew D. Browse this author |
| Jaffe, Glenn J. Browse this author |
| Nguyen, Quan Dong Browse this author |
| Inomata, Noritaka Browse this author |
| Kwatra, Nisha V. Browse this author |
| Camez, Anne Browse this author |
| Song, Alexandra P. Browse this author |
| Kron, Martina Browse this author |
| Tari, Samir Browse this author |
| Ohno, Shigeaki Browse this author →KAKEN DB |
| Keywords: | Active uveitis |
| adalimumab |
| inactive uveitis |
| non-infectious uveitis |
| ocular inflammation |
| Issue Date: | 2-Jan-2019 |
| Publisher: | Taylor & Francis |
| Journal Title: | Ocular immunology and inflammation |
| Volume: | 27 |
| Issue: | 1 |
| Start Page: | 40 |
| End Page: | 50 |
| Publisher DOI: | 10.1080/09273948.2018.1491605 |
| PMID: | 30015528 |
| Abstract: | Purpose: Report global adalimumab safety and efficacy outcomes in patients with non-infectious uveitis. Methods: Adults with non-infectious intermediate, posterior, or panuveitis were randomized 1:1 to receive placebo or adalimumab in the VISUAL I (active uveitis) or VISUAL II (inactive uveitis) trials. Integrated global and Japan substudy results are reported. The primary endpoint was time to treatment failure (TF). Results: In the integrated studies, TF risk was significantly reduced (hazard ratio [95% CI]) with adalimumab versus placebo (VISUAL I: HR = 0.56 [0.40-0.76], p < 0.001; VISUAL II: HR = 0.52 [0.37-0.74], p < 0.001). In Japan substudies, no consistent trends were observed between groups (VISUAL I: HR = 1.20 [0.41-3.54]; VISUAL II: HR = 0.45 [0.20-1.03]). Adverse event rates were similar between treatment groups in both studies (854 to 1063 events/100 participant-years). Conclusions: Adalimumab lowered time to TF versus placebo in the integrated population; no consistent trends were observed in Japan substudies. Safety results were consistent between studies. |
| Rights: | http://creativecommons.org/licenses/by-nc/3.0/ |
| Type: | article |
| URI: | http://hdl.handle.net/2115/74631 |
| Appears in Collections: | 医学院・医学研究院 (Graduate School of Medicine / Faculty of Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
|
